Chinese Medicines in Diabetic Retinopathy Therapies
Back to article page
Review|Updated:2021-08-27
|
Chinese Medicines in Diabetic Retinopathy Therapies
Chinese Medicines in Diabetic Retinopathy Therapies
Chinese Journal of Integrative Medicine2019年25卷第4期 页码:316-320
Affiliations:
Department of Ophthalmology, Jiaxing Traditional Chinese Medicine Hospital Affiliated to Zhejiang Chinese Medical University, Jiaxing, Zhejiang Province (314000), China
Author bio:
Correspondence to: Prof. ZHU Yong-wei, Tel: 86-573-82055510, E-mail: zywei3950@sina.com
Wei SONG, Yong-wei ZHU. Chinese Medicines in Diabetic Retinopathy Therapies[J]. Chinese Journal of Integrative Medicine, 2019,25(4):316-320.
Wei SONG, Yong-wei ZHU. Chinese Medicines in Diabetic Retinopathy Therapies[J]. Chinese Journal of Integrative Medicine, 2019,25(4):316-320.
Wei SONG, Yong-wei ZHU. Chinese Medicines in Diabetic Retinopathy Therapies[J]. Chinese Journal of Integrative Medicine, 2019,25(4):316-320. DOI: 10.1007/s11655-017-2911-0.
Wei SONG, Yong-wei ZHU. Chinese Medicines in Diabetic Retinopathy Therapies[J]. Chinese Journal of Integrative Medicine, 2019,25(4):316-320. DOI: 10.1007/s11655-017-2911-0.
Chinese Medicines in Diabetic Retinopathy Therapies
摘要
Abstract
Diabetic retinopathy (DR)
a chronic microvascular retinal disorder leading to retinal nonperfusion and ischemia
is one of the leading causes of blindness among individuals of working age. Inflammation and neovascularization play important roles in the development of DR
especially proliferative DR (PDR). Therapies with Chinese medicines (CMs) that improve microcirculation complementary to conventional treatments increase the chances of delaying PDR development and improving visual acuity in diabetes patients. This review aimed to introduce promising CMs targeting DR patients in clinical practice
together with their underlying molecular mechanisms.
Schisandrin B Protects against Ischemic Brain Damage by Regulating PI3K/AKT Signaling in Rats
Polypeptide from Moschus Suppresses Lipopolysaccharide-Induced Inflammation by Inhibiting NF-κ B-ROS/NLRP3 Pathway
相关作者
暂无数据
相关机构
Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine
Department of Integrated Traditional Chinese and Western Medicine, Shanghai Skin Disease Hospital, Tongji University School of Medicine
Department of Neurology, The First Hospital of Quanzhou Affiliated to Fujian Medical University
Department of Neurosurgery, Fujian Medical University Union Hospital